Analysis of a maternal health medicines pipeline database 2000-2021: New candidates for the prevention and treatment of fetal growth restriction
Analysis of a maternal health medicines pipeline database 2000-2021: New candidates for the prevention and treatment of fetal growth restriction
复制标题
DOI：
10.1111/1471-0528.17392
复制
发表时间：
2023-02-05
影响因子：
5.8
通讯作者：
Vogel, Joshua P.
中科院分区：
文献类型：
--
作者：
Lim, Shao;McDougall, Annie R. A.;Vogel, Joshua P.
目的：加速母亲创新项目建立了一个新的候选药物数据库，该数据库将在2000年至2021年期间针对包括胎儿生长受限在内的五种与怀孕有关的疾病开发。目的是评估用于胎儿生长受限的药物及其在全球临床应用的潜力。设计：景观分析。（重点是低收入和中等收入国家）。样本：正在调查的用于预防或治疗胎儿生长受限的药物、膳食补充剂和生物制剂。通过搜索AdisInsight、PubMed和各种资助和临床试验数据库，创建了一个药物研究管道数据库。临床和临床前候选人的分析是descriptive.Main Outcomes Measures：胎儿生长限制候选人在临床开发中被确定和排名为高，中或低潜力的基础上预先指定的标准，包括疗效，安全性和accessibility.Results：在444个独特的候选人在数据库中的所有五个妊娠相关的条件，63个是胎儿生长限制。其中，31个处于临床开发（I、II或III期），32个处于临床前开发。三个候选人，阿司匹林，l-精氨酸和维生素D，被列为具有高潜力的预防剂。有没有高潜力的候选人治疗胎儿生长受限，虽然五个候选人被列为具有中等潜力：烯丙雌醇，达肝素，ω-3脂肪酸，他达拉非，和联合国国际多种营养素孕妇准备（UNIMMAP）。结论：l-精氨酸，阿司匹林和维生素D是有前途的，高潜力的预防剂胎儿生长受限。根据药物管道，在不久的将来不太可能出现新的用于胎儿生长限制的药理学药物。
Objective: The Accelerating Innovation for Mothers project established a new database of candidate medicines under development between 2000 and 2021 for five pregnancy-related conditions, including fetal growth restriction. The objective was to assess medicines for fetal growth restriction and their potential for clinical use globally.Design: Landscape analysis.Setting: Global (focus on low- and middle-income countries, LMICs).Sample: Drugs, dietary supplements and biologics under investigation for prevention or treatment of fetal growth restriction.Methods: A research pipeline database of medicines was created through searching AdisInsight, PubMed and various grant and clinical trial databases. Analysis of clinical and preclinical candidates were descriptive.Main Outcomes Measures: Fetal growth restriction candidates in clinical development were identified and ranked as high, medium or low potential based on prespecified criteria, including efficacy, safety and accessibility.Results: Of the 444 unique candidates in the database across all five pregnancy-related conditions, 63 were for fetal growth restriction. Of these, 31 were in clinical development (phases I, II or III) and 32 were in preclinical development. Three candidates, aspirin, l-arginine and vitamin D, were ranked as having high potential as preventive agents. There were no high-potential candidates for treating fetal growth restriction, although five candidates were ranked as having medium potential: allylestrenol, dalteparin, omega-3 fatty acids, tadalafil, and United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP).Conclusions: l-Arginine, aspirin and vitamin D are promising, high-potential preventative agents for fetal growth restriction. Based on the medicines pipeline, new pharmacological agents for fetal growth restriction are unlikely to emerge in the near future.